FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077258404> ?p ?o ?g. }

• W2077258404 abstract "You have accessJournal of UrologyInfections/Inflammation of the Genitourinary Tract: Interstitial Cystitis1 Apr 2014PD9-07 HERPES SIMPLEX VIRUS TYPE-1 (HSV-1) VECTOR-MEDIATED GENE THERAPY OF ENDOMORPHIN FOR BLADDER OVERACTIVITY AND NOCICEPTION Hiroki Okada, Darren Wolfe, James Wechuck, James R. Goss, Tsuyoshi Majima, Christopher J. Chermansky, and Naoki Yoshimura Hiroki OkadaHiroki Okada More articles by this author , Darren WolfeDarren Wolfe More articles by this author , James WechuckJames Wechuck More articles by this author , James R. GossJames R. Goss More articles by this author , Tsuyoshi MajimaTsuyoshi Majima More articles by this author , Christopher J. ChermanskyChristopher J. Chermansky More articles by this author , and Naoki YoshimuraNaoki Yoshimura More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.789AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Bladder pain syndrome/interstitial cystitis (BPS/IC) is a debilitating chronic disorder characterized by bladder pain, urinary frequency and urgency. These symptoms are often difficult to treat and, in such cases, narcotic analgesics that act on μ-opioid receptors (MOR) become the treatment of choice; however, the serious side effects limit their use. Therefore, we examine the effect of local delivery of endomorphin, the natural ligand of MOR, on bladder overactivity and pain behavior using an engineered, non-replicating herpes simplex virus type 1 (HSV-1) vector in rats. METHODS HSV-1 vectors expressing endomorphin (PGN-412) or a placebo vector were injected into the bladder wall of female SD rats 2 weeks prior to the following studies. (1) Cystometry under the awake condition: Saline was continuously infused into the bladder at a rate of 0.04 ml/min to evaluate bladder activity. After a saline infusion period, bladder overactivity was induced by the instillation of 1µM resiniferatoxin (RTX, a TRPV1 receptor agonist) followed by the washout and instillation of 0.5% acetic acid (AA). (2) Behavioral assessment: RTX (3µM, 0.3 ml) was administered into the bladder and retained for 1 min through a temporary indwelled urethral catheter to evaluate nociceptive behaviors such as licking (lower abdominal licking) and freezing (motionless head-turning) for 15 min. RESULTS (1) Inter-contraction intervals (ICI) during cystometry showed a significant reduction after RTX and AA instillation in both PGN-412-treated (n=5) and placebo vector groups (n=4). However, the reduction rate of ICI by RTX and AA in the PGN-412 group was significantly smaller than those in the placebo vector group (RTX: 54±7% vs. 72±10%, AA: 45±12% vs. 76±7%). (2) Intravesical application of RTX for 1 min significantly increased both licking and freezing behaviors in the placebo vector group (n=10); however, these pain-related behaviors were significantly decreased in the PGN-412 group (n=6) compared to the placebo vector group. CONCLUSIONS HSV-1 vector-mediated endomorphin gene therapy targeting the bladder and bladder afferent pathways reduces bladder overactivity and pain-related behavior induced by nociceptive bladder stimuli in rats. Thus, endomorphin gene therapy could be a new treatment modality of urinary frequency and/or bladder pain in patients with BPS/IC with few adverse events. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e214 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Hiroki Okada More articles by this author Darren Wolfe More articles by this author James Wechuck More articles by this author James R. Goss More articles by this author Tsuyoshi Majima More articles by this author Christopher J. Chermansky More articles by this author Naoki Yoshimura More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ..." @default.
• W2077258404 created "2016-06-24" @default.
• W2077258404 creator A5002037432 @default.
• W2077258404 creator A5011158216 @default.
• W2077258404 creator A5013707634 @default.
• W2077258404 creator A5014966560 @default.
• W2077258404 creator A5017226641 @default.
• W2077258404 creator A5031643211 @default.
• W2077258404 creator A5045164790 @default.
• W2077258404 date "2014-04-01" @default.
• W2077258404 modified "2023-09-25" @default.
• W2077258404 title "PD9-07 HERPES SIMPLEX VIRUS TYPE-1 (HSV-1) VECTOR-MEDIATED GENE THERAPY OF ENDOMORPHIN FOR BLADDER OVERACTIVITY AND NOCICEPTION" @default.
• W2077258404 doi "https://doi.org/10.1016/j.juro.2014.02.789" @default.
• W2077258404 hasPublicationYear "2014" @default.
• W2077258404 type Work @default.
• W2077258404 sameAs 2077258404 @default.
• W2077258404 citedByCount "0" @default.
• W2077258404 crossrefType "journal-article" @default.
• W2077258404 hasAuthorship W2077258404A5002037432 @default.
• W2077258404 hasAuthorship W2077258404A5011158216 @default.
• W2077258404 hasAuthorship W2077258404A5013707634 @default.
• W2077258404 hasAuthorship W2077258404A5014966560 @default.
• W2077258404 hasAuthorship W2077258404A5017226641 @default.
• W2077258404 hasAuthorship W2077258404A5031643211 @default.
• W2077258404 hasAuthorship W2077258404A5045164790 @default.
• W2077258404 hasConcept C104317684 @default.
• W2077258404 hasConcept C126322002 @default.
• W2077258404 hasConcept C126894567 @default.
• W2077258404 hasConcept C15490471 @default.
• W2077258404 hasConcept C159047783 @default.
• W2077258404 hasConcept C170493617 @default.
• W2077258404 hasConcept C185592680 @default.
• W2077258404 hasConcept C2522874641 @default.
• W2077258404 hasConcept C2778508898 @default.
• W2077258404 hasConcept C2779762690 @default.
• W2077258404 hasConcept C2780080261 @default.
• W2077258404 hasConcept C2781196997 @default.
• W2077258404 hasConcept C40767141 @default.
• W2077258404 hasConcept C55493867 @default.
• W2077258404 hasConcept C71924100 @default.
• W2077258404 hasConcept C77411442 @default.
• W2077258404 hasConcept C92087593 @default.
• W2077258404 hasConceptScore W2077258404C104317684 @default.
• W2077258404 hasConceptScore W2077258404C126322002 @default.
• W2077258404 hasConceptScore W2077258404C126894567 @default.
• W2077258404 hasConceptScore W2077258404C15490471 @default.
• W2077258404 hasConceptScore W2077258404C159047783 @default.
• W2077258404 hasConceptScore W2077258404C170493617 @default.
• W2077258404 hasConceptScore W2077258404C185592680 @default.
• W2077258404 hasConceptScore W2077258404C2522874641 @default.
• W2077258404 hasConceptScore W2077258404C2778508898 @default.
• W2077258404 hasConceptScore W2077258404C2779762690 @default.
• W2077258404 hasConceptScore W2077258404C2780080261 @default.
• W2077258404 hasConceptScore W2077258404C2781196997 @default.
• W2077258404 hasConceptScore W2077258404C40767141 @default.
• W2077258404 hasConceptScore W2077258404C55493867 @default.
• W2077258404 hasConceptScore W2077258404C71924100 @default.
• W2077258404 hasConceptScore W2077258404C77411442 @default.
• W2077258404 hasConceptScore W2077258404C92087593 @default.
• W2077258404 hasIssue "4S" @default.
• W2077258404 hasLocation W20772584041 @default.
• W2077258404 hasOpenAccess W2077258404 @default.
• W2077258404 hasPrimaryLocation W20772584041 @default.
• W2077258404 hasRelatedWork W2007297396 @default.
• W2077258404 hasRelatedWork W2035474551 @default.
• W2077258404 hasRelatedWork W2039221211 @default.
• W2077258404 hasRelatedWork W2077601239 @default.
• W2077258404 hasRelatedWork W2081628144 @default.
• W2077258404 hasRelatedWork W2083934770 @default.
• W2077258404 hasRelatedWork W2343347401 @default.
• W2077258404 hasRelatedWork W2392413698 @default.
• W2077258404 hasRelatedWork W2897809264 @default.
• W2077258404 hasRelatedWork W3031473246 @default.
• W2077258404 hasVolume "191" @default.
• W2077258404 isParatext "false" @default.
• W2077258404 isRetracted "false" @default.
• W2077258404 magId "2077258404" @default.
• W2077258404 workType "article" @default.